Patients with the killer breast cancer can now breathe a sigh of relief if the new study published in Impact Journals is anything to go by. The research paper posted in the peer-reviewed journal indicate that it is now possible to eliminate breast cancer-causing cells if they have a particular protein molecule known as estrogen receptor beta. Researchers also reported that they are targeting some other molecules in the breast cancer cell in a bid to develop drugs for this killer condition.
According to the study posted on Impact Journals, breast cancer cells have a host of hormone receptors for estrogen and progesterone. These hormones are important for the growth and functioning of breast cells. Several types of breast cancer exist. However, some of these cases that include the triple negative breast cancer (TNBC) are difficult to treat since they lack the particular hormone receptors that are needed for the hormone therapies to work. There are up to 15 percent of TNBC cases that are diagnosed every year.
Regardless of the significant advancements made in diagnosis and treatment of cancer, patients suffering from TNBC continue to endure since the hormone therapies used in other breast cancer treatments aren’t effective. The TNBC cancer is therefore likely to spread to other organs. The study which was conducted by researchers from the Mayo Clinic in Minnesota aims at understanding how they can characterize molecular signaling pathways in breast cancer cells. This understanding will help them to identify better therapies and treatments for breast cancer, especially the TNBC types.
Oncotarget, a peer-reviewed journal is now publishing these scientific findings, together with numerous others on PubMed, ISI/Web of Science, PubMed Central, Scopus, BIOSIS Previews, Biological Abstracts, and EMBASE. Oncotarget is working closely with high-profile archives and indexes to avail scientific findings to the public, researchers, and clinicians within the shortest time possible. To accelerate the dissemination of the information to the public domain, the Journal is now publishing two issues a week; on Thursday and Fridays. Oncotarget has made history of becoming the first journal to submit a complete issue to PubMed within a few days of online publication.
To know more